Search Results
Your search for A matches 32852 pages
Showing 14251 - 14300Chaga Mushroom
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, explore the current...
How Immunologic Dysregulation in the Multiple Myeloma Microenvironment May Affect Response to CAR T-Cell Therapy
Despite an avalanche of novel therapies approved by the U.S. Food and Drug Administration (FDA) over the past decade in the treatment of multiple myeloma, including proteasome inhibitors and immunomodulatory drugs, this blood cancer remains largely incurable, and nearly 13,000 people are expected...
FDA Approves New Trastuzumab Biosimilar
On June 14, the U.S. Food and Drug Administration (FDA) approved trastuzumab-anns (Kanjinti) for all approved indications of the reference product trastuzumab (Herceptin): for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction...
The Bomb
I sit paralyzed at my desk. Everyone else has left the clinic. I can hear the sound of the broom in the hall as the after-hours cleaning begins. No phones ring, no patients hurry to appointments, no chatter lingers in the air. The silence is oppressive, the air is heavy, and the distance from my...
Growing Up in a Medical Family Planted the Seed for a Career in Oncology for Karen Gelmon, MD
Karen Gelmon, MD, was born and reared in Saskatoon, the largest city in the Canadian province of Saskatchewan. It is surrounded by vast prairie and situated along the Trans-Canada Yellowhead Highway and is home to the University of Saskatchewan. “We lived close to the University,” she shared. “My...
Trifluridine/Tipiracil in Recurrent, Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
In the Clinic provides overviews of novel hematology and oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 22, trifluridine/tipiracil...
Endowment Helps George Washington University Cancer Center to Create Position of Dr. Cyrus Katzen Family Director
The George Washington University (GW) Cancer Center has announced the establishment of the Dr. Cyrus Katzen Family Director of the GW Cancer Center, thanks to a gift from GW alumnus and former Board of Trustee member Jay Katzen, MD. The gift will support the ongoing growth and expansion of the GW ...
Willie Underwood III, MD, MSc, MPH, Elected to AMA Board of Trustees
The American Medical Association (AMA) announced the election of Willie Underwood III, MD, MSc, MPH, a urologist based in Buffalo, New York, to its Board of Trustees. A board-certified urologic surgeon specializing in prostate cancer, Dr. Underwood has been an active leader in organized medicine...
Erratum
In the June 10, 2019, issue of The ASCO Post, a photo on page 69, in an article about the National Comprehensive Cancer Network Board of Directors, was incorrectly identified as Ronald Walters, MD, of The University of Texas MD Anderson Cancer Center. The photo was actually of Roland B. Walter,...
Joann Sweasy, PhD, Joins University of Arizona Cancer Center as Associate Director for Basic Sciences
Joann Sweasy, PhD, an expert in DNA repair and genomic instability, has joined the University of Arizona Cancer Center as Associate Director for Basic Sciences. Dr. Sweasy also has been appointed to a joint faculty position at the University of Arizona College of Medicine, Tucson, in the...
FDA Approves First-Line Ivosidenib for IDH1-Mutated AML
On May 2, the U.S. Food and Drug Administration (FDA) expanded its approval of ivosidenib (Tibsovo) to include newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that ...
Does Radioactive Iodine Treatment for Hyperthyroidism Increase the Risk of Cancer Mortality?
Findings from a study of patients who received radioactive iodine treatment for hyperthyroidism show a modest association between the dose of treatment and long-term risk of death from solid cancers, including breast cancer. The study, led by researchers at the National Cancer Institute (NCI), was...
Risk-Prediction Model Aims to Predict Incident Lung Cancer in Patients With a Pulmonary Nodule
A risk-prediction model developed using clinical and radiologic features could stratify individuals presenting with a lung nodule as having a high or low risk for lung cancer, according to a study published by Nemesure et al in Cancer Prevention Research. “While lung nodules are not...
Benefit Seen With Targeted Therapies in Elderly and Medically Complex Patients With Metastatic RCC
Many elderly and medically complex patients with metastatic renal cell carcinoma (RCC)—who are often underrepresented in clinical trials—saw overall survival benefits from treatment with targeted therapies, according to a study that analyzed 13 years of data on Medicare patients...
Mortality After Breast Cancer Among Childhood Cancer Survivors
In an analysis from the Childhood Cancer Survivor Study (CCSS) reported in the Journal of Clinical Oncology, Moskowitz et al found a significant increase in overall mortality among childhood cancer survivors who developed breast cancer vs matched controls. A numeric increase in breast cancer...
Anti-KIR3DL2 Monoclonal Antibody for Relapsed or Refractory Cutaneous T-Cell Lymphoma
In a phase I trial reported in The Lancet Oncology, Bagot et al found that IPH4102—a first-in-class monoclonal antibody targeting KIR3DL2—was safe and showed activity in patients with relapsed or refractory cutaneous T-cell lymphoma, particularly those with Sézary syndrome....
Long-Term Results of the Omission of Postoperative Radiation to the Pathologically Node-Negative Neck in Primary HNSCC
Long-term results of a single-institution phase II study reported in the Journal of Clinical Oncology by Contreras et al showed that the omission of postoperative radiation therapy to the pathologically negative (PN0) neck was associated with good outcomes among patients with primary head and neck...
ESMO World GI 2019: BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAF V600E–Mutated Metastatic Colorectal Cancer
The three-drug combination of encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer, according to results of the phase III BEACON CRC clinical trial. These findings were presented by Kopetz et al at the European...
ESMO World GI 2019: REARRANGE Trial Examines Flexible Regorafenib Dosing in Refractory Metastatic Colorectal Cancer
Regorafenib is often administered to patients with refractory metastatic colorectal cancer. However, some of the adverse events related to the use of this drug often limit its use in clinical practice. A study reported by Argilés et al at the European Society for Medical Oncology (ESMO)...
ESMO World GI 2019: Incidence of Gastric Cancer in Younger Individuals
The incidence of gastric cancer has been increasing in younger individuals, and those under 40 with chronic digestive symptoms should be more actively investigated. These findings follow new data from a retrospective, observational study in Mexico, which showed that 1 in 7 of over 2,000...
Frequency, Complications, and Costs of Diagnostic and Postprogression Biopsies in NSCLC
In a retrospective study reported in the Journal of Oncology Practice, Kelly et al identified the frequency of diagnostic and postprogression biopsies, complication rates, and associated costs in patients with non–small cell lung cancer (NSCLC). The study involved patient data from the...
Chronic Pain in U.S. Cancer Survivors
In a study reported in a research letter in JAMA Oncology, Jiang et al found that 34.6% of cancer survivors in the United States report chronic pain and 16.1% report high-impact chronic pain. The study included data from 4,526 adult cancer survivors identified from 59,770 participants in the...
GOG-0218: Final Overall Survival Results for Addition of Bevacizumab to Chemotherapy in Ovarian Cancer
The final overall survival analysis of the phase III GOG-0218 trial, reported in the Journal of Clinical Oncology by Tewari et al, showed no benefit of adding bevacizumab to chemotherapy in women with newly diagnosed, incompletely resected, advanced ovarian cancer. The trial included 1,873 women...
Role of Liquid Biopsy in Lymphoma
In this episode, The ASCO Post's Editor-in-Chief Dr. James Armitage talks about the International Conference on Malignant Lymphoma (ICML), which he attended recently in Lugano, Switzerland; in particular, Dr. Armitage shares insight from a workshop on bridging liquid biopsy into the management of...
Improve Quality of Life With This Palliative Care Education Resource for Your Patients
Do your patients know that supportive care can help them manage their symptoms and side effects, regardless of age, cancer type, or disease stage? Make sure your patients understand the benefits of palliative care and where to access services with the ASCO Answers Palliative Care booklet. Your...
Positive Findings From Two TAPUR Study Cohorts Presented at the 2019 ASCO Annual Meeting
Positive findings from fully enrolled cohorts in non–small cell lung cancer and metastatic breast cancer from ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR™) study were presented in poster sessions at the 2019 ASCO Annual Meeting. In addition, the study is being expanded to...
Your Stories: Kindred Spirits
It only takes one discovery to change the course of a rare disease. “Kindred Spirits” is a conversation from the Your Stories series between Breelyn Wilky, MD, and a patient with sarcoma whose life she helped save during a recent clinical trial. Developed by Conquer Cancer®, the ASCO Foundation,...
Head and Neck Cancer Researcher Supported by Conquer Cancer®, the ASCO Foundation, Earns Spot in Clinical Cancer Advances 2019
The work of nine researchers who have previously received funding from Conquer Cancer is featured in ASCO’s Clinical Cancer Advances 2019. Visit CONQUER.ORG/CCA for more details. Immunotherapy for Head and Neck Cancer At the Moores Cancer Center at UC (University of California) San Diego Health,...
2019 Presidential Address: Caring for Every Patient, Learning From Every Patient
Welcome, everyone. We are so glad that you are all here today. Those of you attending your first ASCO Annual Meeting: Welcome to this amazing organization. What I’d like to do is to show you some of what ASCO offers, and challenge you all to join in to make a powerful future a reality. We have a...
ASCO Endorses Tobacco-Free Youth Act
Senate Majority Leader Mitch McConnell (R-KY) and Senator Tim Kaine (D-VA) introduced the “Tobacco-Free Youth Act,” which will work to protect youth from tobacco products and electronic nicotine delivery systems by raising the national age of sale from 18 to 21. ASCO endorsed the legislation in a...
FDA Grants Accelerated Approval to Selinexor in Combination With Dexamethasone in Pentarefractory Multiple Myeloma
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selinexor (Xpovio) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two...
Combination Immunotherapy and Inhibitors of DNA Damage Repair in the Treatment of Small Cell Lung Cancer
Unlike non–small cell lung cancer (NSCLC), which has seen a paradigm shift in treatment modalities with the discovery of genetic signatures (including EGFR mutations) that are responsive to targeted drugs, systemic treatment of small cell lung cancer (SCLC) has remained largely unchanged for over...
Actively Recruiting Clinical Trials for Muscle-Invasive and Non–Muscle-Invasive Bladder Cancers
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical research trials for both muscle-invasive and non–muscle-invasive bladder cancers. The studies listed here are evaluating the safety and efficacy of combinations of chemotherapy and...
Expert Point of View: Jiping Wang, MD, PhD
“The jury is still out,” said APACT’s invited discussant, Jiping Wang, MD, PhD, a biostatistician and hepatobiliary pancreas surgical oncologist at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston. “The final overall survival analysis is needed to know the real benefit from...
APACT Trial: Nab-paclitaxel/Gemcitabine vs Gemcitabine Alone in Adjuvant Treatment of Pancreatic Cancer
The largest adjuvant trial in pancreatic adenocarcinoma, the global phase III APACT trial, evaluated the combination of adjuvant nab-paclitaxel/gemcitabine vs gemcitabine monotherapy in patients with resected pancreatic cancer. Results of the study were reported by Margaret A. Tempero, MD, of the...
Expert Point of View: Carlos H. Barrios, MD
“Margetuximab pLUS capecitabine may represent a new alternative combination for third-line treatment of HER2-positive metastatic breast cancer,” said -SOPHIA’s invited discussant Carlos H. Barrios, MD, of the Centro de Pesquisa em Oncologia and Latin American Cooperative Oncology Group in Porto...
SOPHIA Trial Tests Margetuximab in Heavily Pretreated Patients With HER2-Positive Metastatic Breast Cancer
In the phase III SOPHIA trial of 536 heavily pretreated patients with HER2-positive metastatic breast cancer, the novel anti-HER2 antibody margetuximab plus chemotherapy led to significant improvements in progression-free survival, response, and clinical benefit compared with...
Expert Point of View: Andrea Necchi, MD
Formal discussant of the EV-201 trial, Andrea Necchi, MD, of the Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy, found the data pending phase III studies promising: “This study explored enfortumab vedotin in a newly defined population who failed to respond to prior chemotherapy and...
Enfortumab Vedotin After Checkpoint Inhibition in Metastatic Urothelial Cancer
A phase II study found that treatment with the antibody-drug conjugate enfortumab vedotin achieved responses in 44% of patients with locally advanced or metastatic urothelial cancer previously treated with platinum chemotherapy and a checkpoint inhibitor. This is a noteworthy study because it...
Do Statins Lower the Risk of Cardiovascular Complications in Patients Treated With Radiotherapy to the Chest, Neck, or Head?
Patients with cancer who took cholesterol-lowering statin medication following radiation therapy of the chest, neck, or head had significantly reduced risk of suffering a stroke—and possibly other cardiovascular complications—according to research published by Boulet et al in...
SNMMI 2019: Phase I/II Trial of Lutetium-177–PSMA-617 Plus Idronoxil in Metastatic Castration-Resistant Prostate Cancer
A novel therapy using two targeted treatments for prostate cancer has been shown to maximize efficacy while reducing side effects, according to research presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and published by Emmett et al in The Journal ...
Expert Point of View: William P. Harris, MD
The efficacy results of Alliance A021202 suggest that pazopanib is another promising systemic option for carcinoid tumors, according to William P. Harris, MD, Associate Professor of Medicine at the University of Washington and Fred Hutchinson Cancer Research Center, Seattle. “Progression-free...
Study Shows Benefit With Pazopanib in Treatment of Carcinoid Tumors
Pazopanib significantly improved progression-free survival by 47% in patients with progressive carcinoid tumors, in a prospective randomized phase II trial presented at the 2019 ASCO Annual Meeting.1 “With these results, Alliance A021202 becomes the first randomized study to show that the vascular...
SNMMI 2019: Vest to Personalize Lu-177 Dotatate Therapy for Neuroendocrine Tumors
Researchers at the University of Washington are developing a user-friendly vest with technology that collects data to tailor personalized therapy for patients with metastatic, somatostatin receptor 2–positive neuroendocrine tumors (NETs). Their study was presented at the 2019 Annual Meeting...
Expert Point of View: Jordan Berlin, MD
Jordan Berlin, MD, the Ingram Professor of Cancer Research and Professor of Medicine at Vanderbilt University Medical Center, Nashville, discussed the FOxTROT study at the oral session. “FOxTROT did reach its targeted hazard ratio, but the bottom line is the P value did not quite make it to where...
Study Supports Neoadjuvant Chemotherapy in Operable Colon Cancer
For patients with operable colon cancer, neoadjuvant chemotherapy resulted in numerous benefits in the FOxTROT trial but did not reach target significance for the primary endpoint. The study was presented at the 2019 ASCO Annual Meeting by Matthew T. Seymour, MD, of the University of Leeds School...
Expert Point of View: Hanna K. Sanoff, MD, MPH
Study discussant Hanna K. Sanoff, MD, MPH, of the University of North Carolina Lineberger Comprehensive Center, summarized the key results of VISNU-1: first, survival is shorter for patients with high circulating tumor cell (CTC) count; second, the incremental benefit from FOLFOXIRI (fluorouracil...
Targeting FOLFOXIRI Plus Bevacizumab to a Metastatic Colorectal Cancer Subset
In a population of patients with metastatic colorectal cancer deemed to be at high risk by the presence of circulating tumor cells (CTCs), first-line treatment with FOLFOXIRI plus bevacizumab improved progression-free survival by about 3 months, compared with modified FOLFOX plus bevacizumab,...
Expert Point of View: David P. Ryan, MD
The primary analysis of the IDEA trial demonstrated that low-risk stage III colorectal cancer could be acceptably treated with 3 months of capecitabine plus oxaliplatin (CAPOX), invited discussant David P. Ryan, MD, Chief of Hematology/Oncology at Massachusetts General Hospital Cancer Center,...
IDEA Collaboration Turns to Duration of Adjuvant Treatment in Stage II Colon Cancer
The findings of the landmark IDEA trial in stage III colorectal cancer, presented at the 2017 ASCO Annual Meeting and subsequently published in The New England Journal of Medicine,1 were upheld by a subsequent analysis by the same group, the International Duration Evaluation of Adjuvant...
